WebDoctor Encyclopedia

Endocrine

Pituitary neuroendocrine tumour (pituitary adenoma)

A pituitary neuroendocrine tumour, or pituitary adenoma, is a usually benign growth of the pituitary gland. It can cause hormone excess, hormone deficiency or loss of side vision.

Medically reviewed Last reviewed November 15, 2026

What is a pituitary neuroendocrine tumour?

A pituitary neuroendocrine tumour (PitNET), still widely called a pituitary adenoma, is a growth that starts in the hormone-making cells of the front part of the pituitary gland (the anterior pituitary). The pituitary is a pea-sized gland at the base of the brain that controls many other glands, including the thyroid, the adrenal glands, the ovaries and the testes.

Almost all of these tumours are non-cancerous in behaviour: they grow slowly and very rarely spread to other parts of the body. They matter because of where they are and what they do. Some make too much of a hormone, some press on the nerves to the eyes, and some squeeze the normal gland so that it makes too little hormone.

The name “pituitary neuroendocrine tumour” was introduced by pathologists in 2017 and adopted in the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022). It reflects the fact that these are neuroendocrine tumours that can, in a small minority, invade nearby structures or spread. In everyday clinical practice, both names are used.

Pituitary tumours are common and usually very treatable. Many people are cured by surgery or controlled with tablets or injections, and most have a normal life expectancy once the hormone problems are corrected.

1. How common is it?

Pituitary tumours are much more common than once thought. Small, harmless ones are found in about 1 in 10 people on autopsy or brain scans done for other reasons. Tumours that cause symptoms are less common but still affect about 1 in 1,000 people.

Feature Details
Prevalence About 80-100 people per 100,000 live with a clinically relevant pituitary tumour
New cases About 4 per 100,000 people each year
Share of brain tumours About 15% of all tumours inside the skull
Age Most often diagnosed at 30-60; uncommon in children (about 2-6% of cases)
Sex Prolactinomas and Cushing disease are more common in women; non-functioning tumours are slightly more common in men and older adults
Most common types Prolactinoma (about 40-60%) and non-functioning tumours (about 25-40%)

2. Types of pituitary neuroendocrine tumour

Pituitary tumours are described in two ways: by size and by whether they make an active hormone. The pathologist adds a third description: the cell lineage, which tells which type of pituitary cell the tumour came from.

2.1 By size

Size group Size Typical features
Microadenoma Smaller than 10 mm Usually found because of hormone excess; rarely presses on nearby structures
Macroadenoma 10 mm or larger May press on the optic nerves or the normal gland; may grow sideways into the cavernous sinus
Giant adenoma 40 mm or larger Uncommon; often hard to remove completely

2.2 By hormone activity

Tumour type Hormone made in excess Resulting condition
Prolactinoma (lactotroph tumour) Prolactin Hyperprolactinaemia: periods stop, breast milk leaks, low sex drive, infertility
Somatotroph tumour Growth hormone (GH) Acromegaly in adults; gigantism in children and teenagers
Corticotroph tumour Adrenocorticotropic hormone (ACTH) Cushing disease: excess cortisol
Thyrotroph tumour Thyroid-stimulating hormone (TSH) Overactive thyroid (rare; under 1% of tumours)
Non-functioning tumour No hormone, or an inactive one Symptoms from size and pressure; most are gonadotroph tumours

2.3 By cell lineage (WHO 2022)

The WHO 2022 classification groups tumours by the transcription factors that control how pituitary cells develop. This is tested on the removed tissue with special stains.

Lineage Transcription factor Tumour types included
PIT1 lineage PIT1 Somatotroph, lactotroph, mammosomatotroph, thyrotroph and some plurihormonal tumours
TPIT lineage TPIT Corticotroph tumours (including “silent” corticotroph tumours)
SF1 lineage SF1 Gonadotroph tumours (the most common non-functioning type)
No lineage None Null cell tumours (rare) and plurihormonal tumours without a clear lineage

Some subtypes are known to behave more aggressively, including sparsely granulated somatotroph tumours, Crooke cell tumours, silent corticotroph tumours, immature PIT1-lineage tumours and lactotroph tumours in men. The old term “atypical adenoma” is no longer used. Tumours that have spread are now called metastatic PitNETs rather than pituitary carcinomas.

3. Causes and risk factors

Most pituitary tumours are sporadic: they arise by chance from gene changes in a single pituitary cell, and no cause is found. They are not caused by stress, diet or injury.

About 5% are linked to an inherited condition, which is more likely when the tumour appears in childhood or early adulthood, or when relatives are affected.

Inherited condition Gene Pituitary features Other features
Multiple endocrine neoplasia type 1 (MEN1) MEN1 Prolactinoma most often; can be any type Overactive parathyroid glands, pancreatic neuroendocrine tumours
Familial isolated pituitary adenoma (FIPA) with AIP mutation AIP Large GH- or prolactin-secreting tumours in young people; a common cause of gigantism None outside the pituitary
Carney complex PRKAR1A GH excess Spotty skin pigmentation, heart myxomas, adrenal disease
MEN4 CDKN1B Pituitary tumours Parathyroid and other endocrine tumours
X-linked acrogigantism GPR101 duplication Gigantism starting in infancy Usually none
SDH-related syndromes SDHx genes Rare pituitary tumours Paragangliomas and phaeochromocytomas

Among sporadic tumours, a GNAS mutation is found in about 40% of somatotroph tumours, and USP8 mutations in about a third to a half of corticotroph tumours. These findings do not change treatment for most people yet.

4. How does it look?

4.1 On the outside

The tumour itself cannot be seen, but hormone excess can change a person’s appearance over months or years. These changes are often so gradual that family members do not notice them, and comparing old photographs can help.

Condition Visible changes
Acromegaly Larger hands and feet (rings and shoes no longer fit); coarser face with a prominent brow, larger nose, lips and tongue; jaw that juts forward; wider gaps between teeth; thick, oily, sweaty skin; skin tags
Gigantism Very fast growth in height in a child or teenager, well above the family pattern
Cushing disease Rounded, red face (“moon face”); weight gain around the trunk with thin arms and legs; fat pad at the back of the neck; wide purple stretch marks; thin skin that bruises easily; acne and extra facial hair in women
Prolactinoma Usually no visible change; sometimes milky discharge from the nipples; breast enlargement in men
Large tumour of any type A drooping eyelid or a squint if the tumour reaches the nerves that move the eye

4.2 On scans

The best test is a pituitary MRI scan with contrast dye, using thin slices through the gland.

  • A microadenoma usually shows as a small area that takes up contrast more slowly than the normal gland, so it looks darker on early images.
  • A macroadenoma often has a “snowman” or “figure of eight” shape, because it is pinched where it grows up through the opening at the top of the pituitary fossa.
  • The scan shows whether the tumour touches or lifts the optic chiasm, where the nerves to the eyes cross.
  • It also shows whether the tumour has grown into the cavernous sinus, the space beside the gland that holds the carotid artery. This is graded with the Knosp scale (0-4).
  • Bleeding inside the tumour, as in pituitary apoplexy, shows as a bright area on certain sequences.

4.3 Under the microscope

Pituitary tumour cells look fairly uniform and lose the normal mixed pattern of the gland. The pathologist uses stains for pituitary hormones, the transcription factors PIT1, TPIT and SF1, and keratin to classify the tumour. The Ki-67 index, a measure of how many cells are dividing, is also recorded, although on its own it does not predict behaviour reliably.

5. Symptoms

Symptoms depend on which hormone is affected and how large the tumour is. Many people have symptoms for years before diagnosis, because the early signs are vague.

5.1 Symptoms of hormone excess

Condition Common symptoms
Prolactinoma (women) Irregular or absent periods, milky nipple discharge (galactorrhoea), difficulty getting pregnant, vaginal dryness, low sex drive
Prolactinoma (men) Low sex drive, erection problems, reduced fertility; tumours are often found larger, with headaches or sight problems
Acromegaly Joint pain, headaches, heavy sweating, carpal tunnel syndrome, snoring and sleep apnoea, tiredness; high blood pressure, diabetes and heart enlargement over time
Cushing disease Weight gain, muscle weakness (difficulty climbing stairs), mood changes, depression or poor sleep, high blood pressure, diabetes, thin bones and fractures, frequent infections
TSH-secreting tumour Palpitations, weight loss, heat intolerance, tremor, anxiety, sometimes a goitre

5.2 Symptoms of pressure from a large tumour

Symptom Why it happens
Loss of side vision The tumour presses on the optic chiasm; classically both outer halves of the visual field are lost (bitemporal hemianopia). People may bump into things or have trouble driving
Blurred or reduced vision Pressure on one optic nerve
Headache Stretching of the membranes around the gland
Double vision or drooping eyelid Growth into the cavernous sinus affects the nerves that move the eye
Symptoms of hormone deficiency Pressure on the normal gland; see below

5.3 Symptoms of hormone deficiency (hypopituitarism)

  • Low cortisol: tiredness, weakness, dizziness, nausea, weight loss, low blood pressure. This can become life-threatening during illness.
  • Low thyroid hormone: tiredness, feeling cold, weight gain, constipation.
  • Low sex hormones: irregular or absent periods, low sex drive, erection problems, loss of body hair, thinning bones.
  • Low growth hormone: poor growth in children; low energy and more body fat in adults.

Excessive thirst and passing large amounts of urine (diabetes insipidus, now also called arginine vasopressin deficiency) is rare with pituitary tumours before surgery. It suggests another diagnosis, such as a craniopharyngioma or inflammation.

5.4 Pituitary apoplexy: an emergency

Sudden bleeding into or loss of blood supply to a pituitary tumour causes pituitary apoplexy. It affects about 2-12% of people with pituitary tumours and is often the first sign of the tumour.

Call emergency services if someone has a sudden, severe headache together with any of: vomiting, sudden loss of vision, double vision, a drooping eyelid, confusion or drowsiness. Urgent steroid treatment can be life-saving, because cortisol levels may drop suddenly.

6. Diagnosis

Diagnosis combines blood tests, MRI and eye tests, usually in a specialist pituitary centre with endocrinologists, neurosurgeons and eye specialists.

6.1 Hormone tests

Test What it shows
Prolactin Very high levels (often above 4,000 mU/L, about 200 ng/mL) suggest a prolactinoma. Moderate levels can be caused by a large non-functioning tumour pressing on the pituitary stalk (“stalk effect”), by medicines or by pregnancy
IGF-1 and growth hormone after a glucose drink High IGF-1 with GH that does not fall after glucose confirms acromegaly
Cortisol tests Late-night saliva cortisol, 24-hour urine cortisol or an overnight dexamethasone test show cortisol excess; ACTH helps show it comes from the pituitary
Inferior petrosal sinus sampling A specialist test that samples blood draining from the pituitary; used when the MRI does not clearly show a corticotroph tumour
Thyroid tests (TSH, free T4) A high free T4 with a normal or high TSH suggests a TSH-secreting tumour; low values together suggest deficiency
Morning cortisol, LH, FSH, testosterone or oestradiol Check for hormone deficiency

A very large prolactinoma can give a falsely low result in some laboratory tests (the “hook effect”). Laboratories dilute the sample when a large tumour is present to avoid this.

6.2 Imaging and eye tests

  • Pituitary MRI with contrast is the main scan. CT is used if MRI is not possible.
  • Formal visual field testing (perimetry) and a check of visual acuity are done for all tumours close to the optic chiasm.
  • Genetic testing is offered to people diagnosed under the age of about 30, to those with a family history, and to anyone with gigantism or features of MEN1.

6.3 Incidental tumours (“incidentalomas”)

Many small tumours are found by chance on scans done for other reasons. Doctors usually check hormone levels and, for larger ones, the visual fields. Small, non-functioning tumours often need only follow-up scans, because most never grow.

7. Treatment

The aims are to correct hormone excess, relieve pressure on the nerves and gland, replace missing hormones, and prevent regrowth. The best treatment depends mainly on the tumour type.

7.1 Treatment by tumour type

Tumour type First choice Other options
Prolactinoma Cabergoline tablets, usually once or twice a week; shrink most tumours and normalise prolactin in about 80-90% Surgery for small, well-placed tumours, intolerance or resistance; radiotherapy rarely
Acromegaly Transsphenoidal surgery Somatostatin analogues (octreotide, lanreotide, pasireotide, oral octreotide), pegvisomant, cabergoline; radiotherapy
Cushing disease Transsphenoidal surgery; remission in about 70-90% of microadenomas at expert centres Medicines (osilodrostat, metyrapone, ketoconazole, levoketoconazole, pasireotide, cabergoline); repeat surgery; radiotherapy; removal of both adrenal glands
TSH-secreting tumour Surgery Somatostatin analogues before or after surgery
Non-functioning tumour Surgery if it affects vision or is growing; observation if small and causing no problems Radiotherapy for regrowth or residual tumour

7.2 Surgery

Most pituitary operations are done through the nose (endoscopic transsphenoidal surgery), without opening the skull. The surgeon passes instruments through the sphenoid sinus at the back of the nose to reach the gland. A hospital stay of a few days is usual.

Aspect Details
Benefits Quick relief of pressure on the optic nerves; vision improves in most people; can cure hormone excess
Common short-term effects Blocked nose, crusting and mild nosebleeds for a few weeks
Possible complications Leak of brain fluid through the nose (a few per cent), temporary diabetes insipidus, low sodium about a week after surgery, new hormone deficiency, rarely meningitis or damage to the carotid artery
After surgery Hormone tests within days to weeks; an MRI after about 3 months; steroid cover until cortisol is checked

7.3 Medicines

Medicine Used for How it works Main side effects
Cabergoline, bromocriptine Prolactinoma; sometimes acromegaly or Cushing disease Dopamine agonists that switch off prolactin release and shrink the tumour Nausea, dizziness, headache; rarely impulse-control problems such as gambling; heart valve checks at high doses
Octreotide, lanreotide (monthly injections) or oral octreotide Acromegaly; TSH-secreting tumours Somatostatin analogues that block GH or TSH release Loose stools, stomach cramps, gallstones
Pasireotide Acromegaly; Cushing disease Broader somatostatin analogue High blood sugar is common
Pegvisomant Acromegaly Blocks the GH receptor and lowers IGF-1 Raised liver enzymes; does not shrink the tumour
Osilodrostat, metyrapone, ketoconazole, levoketoconazole Cushing disease Block cortisol production in the adrenal glands Low cortisol, high blood pressure or low potassium, liver problems (ketoconazole)

7.4 Radiotherapy

Radiotherapy is used when a tumour is left behind or grows back and cannot be controlled with surgery or medicines. It controls tumour growth in more than 90% of people at 10 years, but it acts slowly on hormone levels.

Type When used Points to know
Stereotactic radiosurgery (e.g. Gamma Knife) Small tumours at a safe distance from the optic nerves One session; hormone control may take 1-5 years
Fractionated radiotherapy (including stereotactic and proton techniques) Larger tumours or those close to the optic nerves Daily treatment over 5-6 weeks
Late effects (both) – Loss of pituitary hormones in up to half of people within 10 years; small risks to vision, of stroke and of a new tumour in the treated area

7.5 Aggressive and metastatic tumours

A small number of tumours keep growing despite surgery, medicines and radiotherapy. The European Society of Endocrinology guideline (2025) recommends temozolomide, a chemotherapy tablet, as the first drug treatment for these tumours. About 40% respond. Options when it fails include immunotherapy (ipilimumab with nivolumab), drugs that block blood vessel growth such as bevacizumab, and peptide receptor radionuclide therapy in clinical trials.

7.6 Hormone replacement

People with hormone deficiency need lifelong replacement, adjusted by an endocrinologist.

Missing hormone Replacement
Cortisol Hydrocortisone tablets; extra doses during illness (“sick day rules”) and an emergency injection kit
Thyroid hormone Levothyroxine tablets
Sex hormones Testosterone, or oestrogen with progesterone; fertility treatment when pregnancy is wanted
Growth hormone Daily or weekly injections in children and selected adults
Vasopressin (if diabetes insipidus) Desmopressin tablets, melts or nasal spray

8. Outlook

The outlook for most people with a pituitary tumour is very good. The tumours do not usually shorten life once hormone excess is controlled and missing hormones are replaced.

Situation Typical outcome
Prolactinoma on cabergoline Prolactin normal in most; about a third can stop treatment after 2 or more years with normal levels and a shrunken tumour, though some relapse
Acromegaly Surgery cures about 75-90% of microadenomas and about 40-50% of macroadenomas; life expectancy is near normal once GH and IGF-1 are controlled
Cushing disease Remission after surgery in most microadenomas, but recurrence in about 10-25% over 10 years; untreated disease raises the risk of heart disease, infection and death
Non-functioning tumour Vision improves after surgery in most people; regrowth in about 1 in 3 over 10 years if tumour is left behind, less after radiotherapy
Aggressive or metastatic tumour Rare; outlook varies widely, with treatment now extending survival for several years in many cases

Long-term follow-up is important, because tumours can regrow and hormone deficiencies can develop many years later. Many people with treated acromegaly or Cushing disease have lasting joint, heart, mood or weight problems that need ongoing care.

9. Living with a pituitary tumour

  • Carry a steroid emergency card if you take hydrocortisone, and learn the sick day rules. Your family should know how to give an emergency injection.
  • Keep to your follow-up appointments, including MRI scans, blood tests and eye checks.
  • Tell the driving authority if your vision is affected, as required in many countries.
  • Women with a prolactinoma who become pregnant should tell their specialist straight away. Cabergoline is usually stopped when pregnancy is confirmed, and large tumours are watched closely.
  • Tiredness, low mood and weight changes are common even after successful treatment. Mention them, because they are often treatable.
  • Patient organisations such as the Pituitary Foundation (UK), the Pituitary Network Association and the Pituitary Society offer information, helplines and support groups.

10. Frequently asked questions

Question Answer
Is a pituitary tumour a brain tumour? It sits at the base of the brain but grows from the pituitary gland, not from brain tissue. It is usually managed by endocrinologists and pituitary surgeons
Is it cancer? Almost always not in the usual sense. Fewer than 0.5% spread to other parts of the body
Will I need surgery? Not always. Prolactinomas are usually treated with tablets, and small non-functioning tumours are often just monitored
Can it come back? Yes, which is why long-term follow-up is needed. Most regrowth is slow and treatable
Can I have children? Usually yes. Restoring normal prolactin often restores fertility, and fertility treatment can help when hormones are missing

Resources

  1. Asa, S.L. et al. (2017) ‘From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal’, Endocrine-Related Cancer, 24(4), pp. C5-C8.
  2. Asa, S.L., Mete, O., Perry, A. and Osamura, R.Y. (2022) ‘Overview of the 2022 WHO classification of pituitary tumors’, Endocrine Pathology, 33(1), pp. 6-26.
  3. WHO Classification of Tumours Editorial Board (2022) Endocrine and Neuroendocrine Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  4. Ezzat, S. et al. (2004) ‘The prevalence of pituitary adenomas: a systematic review’, Cancer, 101(3), pp. 613-619.
  5. Daly, A.F. et al. (2006) ‘High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium’, Journal of Clinical Endocrinology and Metabolism, 91(12), pp. 4769-4775.
  6. Molitch, M.E. (2017) ‘Diagnosis and treatment of pituitary adenomas: a review’, JAMA, 317(5), pp. 516-524.
  7. Melmed, S. (2020) ‘Pituitary-tumor endocrinopathies’, New England Journal of Medicine, 382(10), pp. 937-950.
  8. Petersenn, S. et al. (2023) ‘Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement’, Nature Reviews Endocrinology, 19(12), pp. 722-740.
  9. Giustina, A. et al. (2024) ‘Consensus on criteria for acromegaly diagnosis and remission’, Pituitary, 27(1), pp. 7-22.
  10. Fleseriu, M. et al. (2021) ‘Consensus on diagnosis and management of Cushing’s disease: a guideline update’, Lancet Diabetes & Endocrinology, 9(12), pp. 847-875.
  11. Briet, C. et al. (2015) ‘Pituitary apoplexy’, Endocrine Reviews, 36(6), pp. 622-645.
  12. Raverot, G. et al. (2025) ‘Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas’, European Journal of Endocrinology, 192(6), pp. R45-R78.
  13. National Cancer Institute (2026) Pituitary Tumors Treatment (PDQ). Available at: https://www.cancer.gov/types/pituitary/treatment (Accessed: October 2026).
  14. Pituitary Foundation (2026) Pituitary conditions. Available at: https://www.pituitary.org.uk/ (Accessed: October 2026).

Prepared by the editorial team, October 2026.